Arazlo is owned by Bausch.
Arazlo contains Tazarotene.
Arazlo has a total of 1 drug patent out of which 0 drug patents have expired.
Arazlo was authorised for market use on 18 December, 2019.
Arazlo is available in lotion;topical dosage forms.
Arazlo can be used as topical treatment of acne vulgaris in patients 9 years of age and older.
The generics of Arazlo are possible to be released after 11 May, 2038.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11311482||BAUSCH||Topical compositions and methods for treating skin diseases|| |
(15 years from now)
|New Product (NP)||Dec 18, 2022|
Drugs and Companies using TAZAROTENE ingredient
Market Authorisation Date: 18 December, 2019
Treatment: Topical treatment of acne vulgaris in patients 9 years of age and older
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic